SAN DIEGO, Dec. 12, 2016 /PRNewswire/ -- Forge Therapeutics, Inc. announced today that new preclinical data on its novel class of antibiotic targeting LpxC for treating infections by Gram-negative drug resistant bacteria will be presented at the American Society of Microbiology Conference held in Washington, DC from December 11-14, 2016.

www.ForgeTherapeutics.com

Presentation details:

Conference Title:

ASM Conference on Antibacterial Development

Poster presentation:

Monday, December 12 from 7:00pm to 8:30pm

Poster title:

#35 Antimicrobial activity of non-hydroxamate LpxC inhibitors

Conference location:

Omni Shoreham Hotel
2500 Calvert Street, NM,
Washington, DC 20008

 

Conference website:   http://conferences.asm.org/index.php/upcoming-conferences/asm-conference-on-antibacterial-development

About LpxC
Drug resistant Gram-negative bacteria are regarded as an extremely dangerous public health threat, therefore, novel antibiotics targeting Gram-negative bacteria are desperately needed. LpxC is a highly sought after target only found in Gram-negative bacteria.  Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious and tolerated in vivo, and effective against drug resistance mechanisms including mcr-1, KPC, and NDM.  

About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit www.ForgeTherapeutics.com.

Contact:
Info@ForgeTherapeutics.com

Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-announces-novel-antibiotic-presentation-at-the-american-society-of-microbiology-conference-on-antibacterial-development-300376235.html

SOURCE Forge Therapeutics, Inc.

Copyright 2016 PR Newswire